Bacteriophage susceptibility varies within chronic Pseudomonas aeruginosa lung infections
- 1Yale University
Abstract
Phage therapy is receiving renewed interest in the face of rising rates of antibiotic resistance. One drawback of phages as antibiotic agents is their high host specificity: phages can often only kill a subset of strains within a bacteria species. Phage specificity may be especially problematic for chronic infections, which tend to be genetically diverse, suggesting they may contain variation in phage susceptibility. Such within-population variation in phage susceptibility could make phage treatment less effective, however the extent of this variation in chronic bacterial infections has not been thoroughly studied. To address this gap, we investigated variation in phage susceptibility in four populations of Pa derived from chronic lung infections in people with cystic fibrosis. We first measured the lytic efficiency of 12 virulent phages across 40 isolates from each patient, which revealed substantial variation in susceptibility to four LPS-targeting phages in two of four lung-derived populations. Genomic analysis suggested that within-population variation in phage susceptibility was not explained by the acquisition or loss of phage defense systems, as phage defense system carriage did not strongly vary within lung-derived populations. Conversely, phylogenetic analysis of isolates from one lung-derived population revealed that some evolutionary transitions in phage susceptibility coincided with mutations in genes involved in LPS biosynthesis. This association suggested that within-patient diversification in cell-surface features may have been responsible for variation in phage susceptibility in this population. Finally, phenotypic characterization of lung-derived isolates revealed favorable clinical associations between phage susceptibility and antibiotic resistance in one population. However, associations were largely absent in other populations, suggesting the potential to use phages to drive favorable phenotypic shifts is limited in bacterial infections with existing variation in phage susceptibility. Collectively, this work shows that phage susceptibility can vary within Pa chronic infections in the lungs of people with cystic fibrosis, possibly as a consequence of standing variation in cell-surface features. This variation poses a challenge for phage therapy, necessitating new approaches to ensure high efficacy in the face of extreme within-patient heterogeneity.
Related
- Bacteriophage Therapy in Cystic Fibrosis: Emerging Strategies for Managing Chronic Pseudomonas aeruginosa Infections.
- Refractory Pseudomonas aeruginosa Bronchopulmonary Infection After Lung Transplantation for Common Variable Immunodeficiency Despite Maximal Treatment Including IgM/IgA-Enriched Immunoglobulins and Bacteriophage Therapy
- Bacteriophage PAK_P3 genome structuration and dynamics during infection of Pseudomonas aeruginosa reveal specific interaction patterns
- The bacteriophage transcription factor Gp53 suppresses cell division and regulates Pseudomonas aeruginosa physiology
- A dual-action bacteriophage protein Ped1 degrades DNA and blocks replication in Pseudomonas aeruginosa
BibTeX
@misc{houpt2026bacteriophage,
title = {{Bacteriophage susceptibility varies within chronic Pseudomonas aeruginosa lung infections}},
author = {N. S. Houpt and J. Vanderwoude and S. P. Diggle and P. E. Turner},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.13.758950},
url = {https://www.biorxiv.org/content/10.64898/2026.10.13.758950v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Bacteriophage susceptibility varies within chronic Pseudomonas aeruginosa lung infections
AU - N. S. Houpt
AU - J. Vanderwoude
AU - S. P. Diggle
AU - P. E. Turner
PY - 2026
DA - 2026/10/13
PB - bioRxiv
DO - 10.64898/2026.10.13.758950
UR - https://www.biorxiv.org/content/10.64898/2026.10.13.758950v1
AB - Phage therapy is receiving renewed interest in the face of rising rates of antibiotic resistance. One drawback of phages as antibiotic agents is their high host specificity: phages can often only kill a subset of strains within a bacteria species. Phage specificity may be especially problematic for chronic infections, which tend to be genetically diverse, suggesting they may contain variation in phage susceptibility. Such within-population variation in phage susceptibility could make phage treatment less effective, however the extent of this variation in chronic bacterial infections has not been thoroughly studied. To address this gap, we investigated variation in phage susceptibility in four populations of Pa derived from chronic lung infections in people with cystic fibrosis. We first measured the lytic efficiency of 12 virulent phages across 40 isolates from each patient, which revealed substantial variation in susceptibility to four LPS-targeting phages in two of four lung-derived populations. Genomic analysis suggested that within-population variation in phage susceptibility was not explained by the acquisition or loss of phage defense systems, as phage defense system carriage did not strongly vary within lung-derived populations. Conversely, phylogenetic analysis of isolates from one lung-derived population revealed that some evolutionary transitions in phage susceptibility coincided with mutations in genes involved in LPS biosynthesis. This association suggested that within-patient diversification in cell-surface features may have been responsible for variation in phage susceptibility in this population. Finally, phenotypic characterization of lung-derived isolates revealed favorable clinical associations between phage susceptibility and antibiotic resistance in one population. However, associations were largely absent in other populations, suggesting the potential to use phages to drive favorable phenotypic shifts is limited in bacterial infections with existing variation in phage susceptibility. Collectively, this work shows that phage susceptibility can vary within Pa chronic infections in the lungs of people with cystic fibrosis, possibly as a consequence of standing variation in cell-surface features. This variation poses a challenge for phage therapy, necessitating new approaches to ensure high efficacy in the face of extreme within-patient heterogeneity.
ER -